Authors: Wen Ying Lee, Xiao Chen, Monica Lui, Lee Chen, Tina Zhang, Tommy Flashman, and James Wang.
Hypertension has been known to be one of the most common chronic inflammations of the body affecting lives of many worldwide. Constant elevation of blood pressure limits the organ from performing at its optimal rate, and its effects are more widespread throughout the body. Many prescription drugs have been created and used by affected individuals at a cost-severe financial loss and/or inescapable side effects. The race to discover other alternative treatment leads to newfound attention to stem cell therapy where patients are treated with their own stem cells in the hope of minimizing cost and side effects. The intention of our study is to use SB Cells® to approach hypertension syndromes by testing the gene Heme oxygenase decycling-1 (HMOX-1). HMOX-1 is a critical enzyme that breaks down heme to produce carbon monoxide (CO). CO is an important metabolite that participates in vasodilation and many other anti-inflammation processes. We observed a significant increase in HMOX-1 expression in the blood 24-hours and/or 1-week post-SB cells® treatment. Additionally, blood pressure level of tested patients significantly decreased post treatment.
We envision that this application could one day be used to treat other HMOX1 related diseases such as inflammation as well as cancer.
View/Download pdf